催产素受体单核酸多态性与母婴共同占用和婴儿感官处理有关
Nicki L Aubuchon-Endsley1,2, Madeline Hudson2, Brittany Banh2
1Department of Psychology, Idaho State University, Pocatello, ID 83209, USA.
Children (Basel, Switzerland)
|October 26, 2024
概括
母亲的催产素受体基因变异会影响护理者与婴儿的相互作用和婴儿的感官处理. 患有特定OXTR SNP的母亲表现出改变的同职行为,婴儿有不同的感官回避模式.
科学领域:
- 神经遗传学 神经遗传学
- 发展心理学 发展心理学
- 行为生物学 行为生物学
背景情况:
- 护理人员-婴儿互惠关系影响儿童的发展和健康.
- 有限的研究存在于共同职业和婴儿感官处理.
- 生物心理社会因素,包括母体催产素受体单核酸多态 (OXTR SNPs),是关键的调解者.
研究的目的:
- 调查母亲的OXTR SNP是否会影响与婴儿的共同职业行为.
- 为了确定母体的OXTR SNP是否影响婴儿的感官处理和偏好.
主要方法:
- 利用婴儿发育和母亲健康结果研究的数据.
- 分析了OXTR SNPs的产前唾液和共同职业的产后行为观察.
- 在10,14和18个月时评估婴儿的感觉特征.
主要成果:
- 具有rs53576风险等位基因A的母亲表现出更多的互惠情绪.
- 具有rs2254298风险等位基因A的母亲表现出较少的相互情感性,但更多的意向性.
- 患有rs53576风险等位基因A的母亲的婴儿有更高的感觉回避的几率.
结论:
- 研究结果支持OXTR SNP,护理人员互惠和婴儿发展之间的联系.
- 将之前的研究扩展到共同职业和婴儿感官处理/偏好.
相关概念视频
Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Neurotransmitters
Neurotransmitters are essential chemical messengers within the nervous system, facilitating the communication between neurons. These chemical messengers, varying in function and effect, are critical for sustaining various aspects of neurological health and emotional well-being.


